Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma

Amit Sharma, Eun Joong Kim, Seokgyu Mun, Myung Sun Ji, Bong Geun Chung, Jong Seung Kim

Research output: Contribution to journalArticle

Abstract

In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC.

Original languageEnglish
Pages (from-to)628-633
Number of pages6
JournalDyes and Pigments
Volume163
DOIs
Publication statusPublished - 2019 Apr 1

Fingerprint

Esterases
Chemical activation
Tumors
Pharmaceutical Preparations
Carboxylesterase
Chemotherapy
Prodrugs
Doxorubicin
Cells
Molecules

Keywords

  • Cancer
  • Drug delivery system
  • Hepatocellular carcinoma
  • Targeted therapy
  • Theranostic

ASJC Scopus subject areas

  • Chemical Engineering(all)
  • Process Chemistry and Technology

Cite this

Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma. / Sharma, Amit; Kim, Eun Joong; Mun, Seokgyu; Ji, Myung Sun; Chung, Bong Geun; Kim, Jong Seung.

In: Dyes and Pigments, Vol. 163, 01.04.2019, p. 628-633.

Research output: Contribution to journalArticle

Sharma, Amit ; Kim, Eun Joong ; Mun, Seokgyu ; Ji, Myung Sun ; Chung, Bong Geun ; Kim, Jong Seung. / Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma. In: Dyes and Pigments. 2019 ; Vol. 163. pp. 628-633.
@article{3ab0e6e56a2f4ef2a1329e3a1d2ff8d4,
title = "Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma",
abstract = "In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC.",
keywords = "Cancer, Drug delivery system, Hepatocellular carcinoma, Targeted therapy, Theranostic",
author = "Amit Sharma and Kim, {Eun Joong} and Seokgyu Mun and Ji, {Myung Sun} and Chung, {Bong Geun} and Kim, {Jong Seung}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.dyepig.2018.12.026",
language = "English",
volume = "163",
pages = "628--633",
journal = "Dyes and Pigments",
issn = "0143-7208",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma

AU - Sharma, Amit

AU - Kim, Eun Joong

AU - Mun, Seokgyu

AU - Ji, Myung Sun

AU - Chung, Bong Geun

AU - Kim, Jong Seung

PY - 2019/4/1

Y1 - 2019/4/1

N2 - In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC.

AB - In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC.

KW - Cancer

KW - Drug delivery system

KW - Hepatocellular carcinoma

KW - Targeted therapy

KW - Theranostic

UR - http://www.scopus.com/inward/record.url?scp=85059112331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059112331&partnerID=8YFLogxK

U2 - 10.1016/j.dyepig.2018.12.026

DO - 10.1016/j.dyepig.2018.12.026

M3 - Article

AN - SCOPUS:85059112331

VL - 163

SP - 628

EP - 633

JO - Dyes and Pigments

JF - Dyes and Pigments

SN - 0143-7208

ER -